Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

rhythm pharmaceuticals inc - RYTM

RYTM

Close Chg Chg %
101.06 1.14 1.13%

Closed Market

102.20

+1.14 (1.13%)

Volume: 422.89K

Last Updated:

Sep 10, 2026, 4:00 PM EDT

Trade Now

Company Overview: rhythm pharmaceuticals inc - RYTM

RYTM Key Data

Open

$99.88

 Day Range

99.88 - 102.87

52 Week Range

74.51 - 122.20

 Market Cap

$7.01B

Shares Outstanding

68.85M

 Public Float

66.12M

Beta

1.97

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.12

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

481.84K

  

RYTM Performance

1 Week
 
 -1.64%
 
1 Month
 
 -12.60%
 
3 Months
 
 14.35%
 
1 Year
 
 5.03%
 
5 Years
 
 678.58%
 

RYTM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About rhythm pharmaceuticals inc - RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

RYTM At a Glance

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street
Boston, Massachusetts 02116-3748
Phone 1-857-264-4280 Revenue 189.76M
Industry Pharmaceuticals: Major Net Income -196,539,000.00
Sector Health Technology 2025 Sales Growth 45.826%
Fiscal Year-end 12 / 2026 Employees 414
View SEC Filings

RYTM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 36.657
Price to Book Ratio 51.727
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -35.715
Enterprise Value to Sales 35.889
Total Debt to Enterprise Value 0.036

RYTM Efficiency

Revenue/Employee 458,350.242
Income Per Employee -474,731.884
Receivables Turnover 7.276
Total Asset Turnover 0.434

RYTM Liquidity

Current Ratio 4.407
Quick Ratio 4.164
Cash Ratio 3.671

RYTM Profitability

Gross Margin 89.497
Operating Margin -101.19
Pretax Margin -103.312
Net Margin -103.574
Return on Assets -44.94
Return on Equity -244.455
Return on Total Capital -51.423
Return on Invested Capital -60.38

RYTM Capital Structure

Total Debt to Total Equity 174.828
Total Debt to Total Capital 63.614
Total Debt to Total Assets 50.527
Long-Term Debt to Equity 169.114
Long-Term Debt to Total Capital 61.535
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rhythm Pharmaceuticals Inc - RYTM

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
23.64M 77.43M 130.13M 189.76M
Sales Growth
+649.46% +227.56% +68.06% +45.83%
Cost of Goods Sold (COGS) incl D&A
3.03M 10.21M 14.08M 19.93M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.40M 1.76M 1.56M 1.34M
Depreciation
629.00K 903.00K 708.00K 438.00K
Amortization of Intangibles
774.00K 855.00K 855.00K 900.00K
COGS Growth
+114.06% +236.91% +37.93% +41.59%
Gross Income
20.61M 67.22M 116.05M 169.83M
Gross Income Growth
+1,085.11% +226.18% +72.63% +46.34%
Gross Profit Margin
+87.19% +86.82% +89.18% +89.50%
2022 2023 2024 2025 5-year trend
SG&A Expense
199.77M 251.58M 381.55M 361.84M
Research & Development
107.73M 134.05M 237.25M 166.90M
Other SG&A
92.03M 117.53M 144.30M 194.94M
SGA Growth
+16.28% +25.94% +51.66% -5.17%
Other Operating Expense
- - - -
-
Unusual Expense
(250.00K) (190.00K) (7.48M) 910.00K
EBIT after Unusual Expense
(178.91M) (184.17M) (258.02M) (192.93M)
Non Operating Income/Expense
2.99M 13.95M 18.37M 17.47M
Non-Operating Interest Income
4.03M 13.95M 14.71M 15.29M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
5.20M 13.89M 20.60M 20.58M
Interest Expense Growth
- +167.10% +48.31% -0.10%
Gross Interest Expense
5.20M 13.89M 20.60M 20.58M
Interest Capitalized
- - - -
-
Pretax Income
(181.12M) (184.11M) (260.26M) (196.04M)
Pretax Income Growth
-160.18% -1.65% -41.36% +24.67%
Pretax Margin
-766.22% -237.79% -200.00% -103.31%
Income Tax
- 564.00K 346.00K 497.00K
Income Tax - Current - Domestic
- - - 1.00K
-
Income Tax - Current - Foreign
- 563.00K 346.00K 497.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(181.12M) (184.68M) (260.60M) (196.54M)
Minority Interest Expense
- - - -
-
Net Income
(181.12M) (184.68M) (260.60M) (196.54M)
Net Income Growth
-160.18% -1.97% -41.11% +24.58%
Net Margin Growth
-766.22% -238.52% -200.27% -103.57%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(181.12M) (184.68M) (260.60M) (196.54M)
Preferred Dividends
- - 3.97M 5.38M
-
Net Income Available to Common
(181.12M) (184.68M) (264.57M) (201.92M)
EPS (Basic)
-3.475 -3.2022 -4.3376 -3.1072
EPS (Basic) Growth
-147.60% +7.85% -35.46% +28.37%
Basic Shares Outstanding
52.12M 57.67M 61.00M 64.98M
EPS (Diluted)
-3.475 -3.2022 -4.3376 -3.1072
EPS (Diluted) Growth
-147.60% +7.85% -35.46% +28.37%
Diluted Shares Outstanding
52.12M 57.67M 61.00M 64.98M
EBITDA
(177.75M) (182.60M) (263.94M) (190.68M)
EBITDA Growth
-5.24% -2.73% -44.55% +27.76%
EBITDA Margin
-751.98% -235.83% -202.83% -100.49%

Snapshot

Average Recommendation BUY Average Target Price 140.188
Number of Ratings 18 Current Quarters Estimate -0.727
FY Report Date 09 / 2026 Current Year's Estimate -3.01
Last Quarter’s Earnings -0.73 Median PE on CY Estimate N/A
Year Ago Earnings -3.11 Next Fiscal Year Estimate -0.666
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 16 16 17
Mean Estimate -0.73 -0.71 -3.01 -0.67
High Estimates -0.57 -0.45 -2.54 0.53
Low Estimate -0.85 -0.93 -3.36 -2.45
Coefficient of Variance -11.67 -18.77 -7.30 -136.81

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 16
OVERWEIGHT 0 0 0
HOLD 2 2 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Rhythm Pharmaceuticals Inc - RYTM

Date Name Shares Transaction Value
Mar 5, 2026 Edward T. Mathers Director 9,969 Other acquisition or disposition 0.00
Mar 5, 2026 Yann Mazabraud EVP, Head of International 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Christopher German Corporate Controller & CAO 4,595 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 5, 2026 Christopher German Corporate Controller & CAO 4,253 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $94.94 per share 403,779.82
Mar 5, 2026 Christopher German Corporate Controller & CAO 1,162 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 117,266 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $99.42 per share 11,658,585.72
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 117,066 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.52 per share 11,767,474.32
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 116,166 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $101.7 per share 11,814,082.20
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 115,097 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103 per share 11,854,991.00
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 114,897 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.84 per share 11,930,904.48
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 113,589 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.27 per share 11,389,569.03
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 111,897 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.92 per share 11,292,645.24
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 111,097 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.1 per share 11,343,003.70
Feb 20, 2026 Hunter C. Smith Chief Financial Officer 110,512 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.28 per share 11,413,679.36

Rhythm Pharmaceuticals Inc in the News